New Urology Products & Services

August 1, 2010

New urology products and services from sanofi-aventis, American Medical Systems, Karl Storz Endoscopy-America, Inc., Ethicon Endo-Surgery, Cook Medical, and GE Healthcare.

FDA approves agent for metastatichormone-refractory prostate Ca

Paris-The FDA recently granted marketing authorization for cabazitaxel (Jevtana) injection in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer (mHRPC) previously treated with docetaxel (Taxotere). Results from a recent phase III clinical trial demonstrated a statistically significantly lower risk of death from mHRPC in patients taking cabazitaxel plus prednisone compared with patients on mitoxantrone (Novantrone) and prednisone.
For more information, visit

New single-incision sling system granted FDA clearance

Endoscopy firm offers capital equipment info via online portal

El Segundo, CA-Karl Storz Endoscopy-America, Inc. has signed a 3-year agreement with Attainia, an online marketplace for capital equipment, to make information available about key solutions for operating room integration and video imaging products. Attainia's Web-based software applications are meant to enable hospitals, health systems, and equipment planners/architects to manage health care projects and budgets more effectively, according to Karl Storz.
For more information, visit

Stapler offers system-wide compression, natural articulation

Cincinnati-The Echelon Flex 45 Endopath Stapler is a new endocutter that provides surgeons with improved access and compression when deploying the commonly used 45-mm staple line, according to manufacturer Ethicon Endo-Surgery. The stapler delivers system-wide compression, natural articulation, and optimal staple formation in a variety of tissue thickness. It is used to cut and staple tissue in a variety of surgical procedures, including urologic, gynecologic, and general surgery.
For more information, visit

Biopsy forceps are engineered to obtain larger tissue samples

Optical imaging agent helps detect nonmuscle-invasive bladder Ca

Waukesha, WI-The FDA recently approved hexaminolevulinate hydrochloride (Cysview) for the detection of nonmuscle-invasive papillary cancer of the bladder. The optical imaging agent is used with the Karl Storz D-Light C Photodynamic Diagnostic system to perform cystoscopy with the blue light setting as an adjunct to the white light setting, according to GE Healthcare, its manufacturer.
For more information, visit

Related Content: